News & Updates

Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
26 Nov 2022

Although the incidence of myocarditis or pericarditis following mRNA COVID-19 vaccination is low, a two- to threefold higher likelihood is seen among individuals who received mRNA-1273 compared to BNT162b2 vaccine, reveals a study.

Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
26 Nov 2022
Immunosuppressant exposure tied to guideline-congruent cervical cancer screening
Immunosuppressant exposure tied to guideline-congruent cervical cancer screening
24 Nov 2022
Anifrolumab for SLE shows favourable benefit–risk profile in extension study
Anifrolumab for SLE shows favourable benefit–risk profile in extension study
22 Nov 2022

Patients with moderate-to-severe systemic lupus erythematosus (SLE) appear to fare well with anifrolumab, with a recent study showing that the drug has an acceptable long-term safety profile and helps maintain reductions in disease activity and glucocorticoid usage.

Anifrolumab for SLE shows favourable benefit–risk profile in extension study
22 Nov 2022
TB rates elevated after ART initiation in PLHIV
TB rates elevated after ART initiation in PLHIV
21 Nov 2022 byRoshini Claire Anthony

People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.

TB rates elevated after ART initiation in PLHIV
21 Nov 2022